The most important milestones in the history of Egis:
Establishment of the company
Presence at the International Humanitarian Exhibition
Opening our first research laboratory in Budapest
Ronin: first heterocyclic sulfonamide drug
Construction and modernization
EGYT (predecessor of Egis) established
New production plant in Körmend
Name changed to Egis
Egis shares were introduced to the Hungarian Stock Exchange
Establishment of Egis Pharmaceuticals LTD polish division - EGIS Polska Sp. z o.o.
Servier aquires 51% of Egis
Extending the offer of drugs EGIS Polska Sp. z o.o.
The development of EGIS Polska Sp. z o.o.
New tablet production plant
Egis Polska Sp. z o.o. moves to a new office
EGIS Polska introduces a combination of ramipril and amlodipine (Egiramlon)
Market Launch of Biosimilar Products
The portfolio of EGIS Polska expends by the family of DIP ointments
A market leader biosimilar product
Purchase of rights to the Biovital brand
EGIS Polska introduces a combination of rozuwastatyna and ezetymib (Rosulip Plus)
A market leader biosimilar product, first successful acquisition
New guidelines for Milurit
25th anniversary of EGIS Polska Sp. z o.o.
Cookies necessary for basic functioning
These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.
Cookies for statistical purposes
They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.